


5. Sun JK, Beaulieu WT, Melia M, et al. Defining “strong” versus “weak” response to antivascular endothelial growth factor treatment for center-involved diabetic macular edema. *Retina*. 2023;43(4):616–623.
6. Ross EL, Hutton DW, Stein JD, et al. Cost-effectiveness of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema treatment: analysis from the diabetic retinopathy clinical research network comparative effectiveness trial. *JAMA Ophthalmol*. 2016;134(8):888–896.
7. Patel NA, Al-Kharsan H, Yannuzzi NA, et al. Aflibercept monotherapy versus bevacizumab-first for diabetic macular edema: a cost analysis based on Diabetic Retinopathy Clinical Research Network Protocol AC results. *Ophthalmol Retina*. 2023;7(5):413–419.
8. Hutton DW, Glassman AR, Liu D, et al. Cost-effectiveness of aflibercept monotherapy vs bevacizumab first followed by aflibercept if needed for diabetic macular edema. *JAMA Ophthalmol*. 2023;141(3):268–274.

## Pictures & Perspectives



### ***Salmonella Enteritidis* Endogenous Endophthalmitis with Abscess of Capsular Bag**

One week after a 6-day bout of watery febrile diarrhea, an 85-year-old pseudophakic White woman, followed up for a relapsed multiple myeloma, presented with sudden unilateral vision loss (20/20000). Severe panuveitis with a massive fibrino-hemorrhagic cyclitic membrane (A) extending to the capsular bag (B) was documented. The results of blood cultures, brain magnetic resonance imaging, whole-body computed tomography scan, and transthoracic echocardiogram were negative. Early vitrectomy confirmed endogenous endophthalmitis caused by *Salmonella enterica* serotype *enteritidis* growing in the vitreous fluid and capsular abscess. Massive inflammation was removed by cleaning fibrin in the sulcus (C) and sticky retrolental abscess (D). Complete healing occurred without subsequent complications: vision improved until 3 months and then remained constant (20/32, Jaeger 1). (Magnified version of Figure A–D is available online at [www.aajournal.org](http://www.aajournal.org)).

OTHMAN MESSALTI, MD<sup>1</sup>

MATHILDE KASPI, MD<sup>1</sup>

THIBAUD GARCIN, MD, PhD<sup>1,2,3</sup>

<sup>1</sup>Ophthalmology Department, University Hospital, Saint-Etienne, France; <sup>2</sup>Ophthalmology Department, Hospital Lariboisiere and Fernand-Widal, Paris, France; <sup>3</sup>Laboratory Biology, Engineering and Imaging for Ophthalmology, BiiO, Federative Institute of Research in Sciences and Health Engineering, Faculty of Medicine, Jean Monnet University, Saint-Etienne, France